Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ardelyx ( (ARDX) ) has issued an update.
Ardelyx, Inc., a company operating in the pharmaceutical or healthcare sector, announced leadership transitions involving two key executives. On December 17, 2025, Elizabeth Grammer, Chief Legal and Administrative Officer, informed the company of her resignation effective December 31, 2025. Following this, she will continue to serve as General Counsel until a successor is appointed and later transition to a Senior Advisor role for two years. Her transition is structured under a detailed agreement that includes salary continuation, bonuses, and other benefits tailored to her role during the advisory period. Additionally, Edward Conner, M.D., Chief Medical Officer, also announced his resignation for personal reasons, effective December 31, 2025. Dr. Laura Williams will temporarily take over as interim Chief Medical Officer, ensuring continuity in the company’s clinical development programs.
The most recent analyst rating on (ARDX) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.
Spark’s Take on ARDX Stock
According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.
Ardelyx’s strong revenue growth and strategic initiatives are promising, but profitability challenges and reliance on debt weigh on the score. Technical indicators suggest potential for a rebound, while the earnings call provides a positive outlook for future growth.
To see Spark’s full report on ARDX stock, click here.
More about Ardelyx
Average Trading Volume: 3,434,917
Technical Sentiment Signal: Buy
Current Market Cap: $1.46B
For a thorough assessment of ARDX stock, go to TipRanks’ Stock Analysis page.